This article first appeared on GuruFocus .
-
Cash and Cash Equivalents:$3.04 million as of the end of December 2025.
-
Total Operating Expenses:$9.72 million for the year 2025, an increase of $3.78 million from 2024.
-
Net Loss:$9.16 million for the year 2025.
Release Date: March 31, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
EXoZymes Inc ( NASDAQ:EXOZ ) has successfully transitioned from a broad platform company to a commercially focused entity, enhancing shareholder value by taking projects further along than initially planned.
-
The company has developed a breakthrough cell-free biomanufacturing platform that allows for the production of rare, high-value molecules quickly, affordably, and at scale, which is a significant advancement over traditional methods.
-
EXoZymes Inc ( NASDAQ:EXOZ ) has made significant progress with its NCT product, achieving high purity and scalability, which positions it well for market entry and potential partnerships.
-
The company is leveraging AI-assisted enzyme engineering tools to enhance its platform capabilities, allowing for the production of novel cannabinoid analogs and other complex natural products.
-
EXoZymes Inc ( NASDAQ:EXOZ ) has maintained a disciplined financial approach, with sufficient liquidity to support ongoing operations and key initiatives into Q2 2026, while exploring non-dilutive funding opportunities to strengthen its financial position.
Negative Points
-
EXoZymes Inc ( NASDAQ:EXOZ ) is still a pre-revenue company, which means it has not yet achieved operating break-even and relies on fundraising to finance its operations.
-
The company faces skepticism from potential partners and investors due to past disappointments in the synthetic biology industry, which could impact its ability to secure favorable licensing terms.
-
There is a lack of visibility into specific milestones and timelines for partnership agreements, which may cause uncertainty among shareholders.
-
The company has experienced an increase in operating expenses, primarily driven by R&D investments and personnel expansion, leading to a net loss for the year.
-
Scaling up production from pilot to commercial scale presents potential challenges, and the company must ensure robust supply chain validation and contract manufacturing partnerships to mitigate risks.
Q & A Highlights
Q: Do you have enough operating cash on the balance sheet to get to operating break-even? When will that occur? A: Michael Heltzen, CEO: We are currently fundraising and plan to start taking in and locking down indications in April. This will finance the company moving forward. Our strategy involves building biomanufacturing assets and tech transfer packages, which provide competitive advantages in specific markets. We aim to create value efficiently, translating efforts into shareholder value through spin-offs, joint ventures, and licensing deals.
Q: Can you provide a clearer milestone roadmap to keep shareholders better informed? A: Michael Heltzen, CEO: We aim to improve communication on milestones, but it's challenging to balance following a roadmap with doing what's best for the company and shareholders. In 2025, we shifted focus to investing in business opportunities like NCT and cannabinoids. Key milestones include human use studies for NCT and completing tech transfer packages for commercial production.
Q: Are you still pursuing a dual-track strategy for cannabinoids, similar to NCT? A: Tyler Korman, CSO: Yes, we are pursuing both rare cannabinoids and new-to-nature cannabinoid analogs. We recently filed a provisional patent for new analogs. While the regulatory environment is shifting, we remain focused on pharmaceutical opportunities for these assets, keeping options open as regulations evolve.
Q: What is the nature of the relationship with Cayman Chemicals going forward? A: Damien Perriman, CCO: Cayman Chemicals has been an incredible partner, demonstrating our process technology's scalability and performance. We plan to continue working with them and other contract manufacturing organizations to ensure robust supply chains for NCT. Key milestones include optimizing process methods, robustness testing, and tech transfer package completion for commercial production readiness in 2027.
Q: Do you see eXoZymes evolving into a pharmaceutical platform company or remaining focused on specific assets? A: Michael Heltzen, CEO: We are doubling down on NCT and cannabinoids, creating significant value. While we focus on flagship efforts, we are also engaging with biotech and pharma companies interested in our core technology. We aim to build more assets on our platform, eventually expanding to licensing alongside spin-outs and joint ventures.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
